17 results about "Vascular inflammation" patented technology

The present invention relates to a polysubstituted imidazolo[4,5-c][1,2]thiazine derivative and a use of an agent comprising same as an active agent, which is useful for infectious diseases associated with vascular inflammation caused by HMGB1 protein activity. It has been found that the polysubstituted imidazolo[4,5-c][1,2]thiazine derivative of the present invention increases the sepsis survival rate as a result of searching for antiseptic effects through CLP-induced sepsis animal experiments. Accordingly, the agent comprising the polysubstituted imidazolo[4,5-c][1,2]thiazine derivative or a pharmaceutically acceptable salt thereof as an active agent may be advantageously used as a therapeutic agent for infectious diseases and vascular inflammatory diseases including sepsis caused by HMGB1 protein activity.

The present application relates to the field of biotechnology, in particular, the present application relates to single domain antibody, bispecific antibody and application thereof, more particularly, the present application relates to single domain antibody, antibody or fusion protein, bispecific antibody, nucleic acid molecule, expression vector, recombinant cell, pharmaceutical composition, pharmaceutical use, detection kit capable of specifically recognizing VEGF and / or ANG-2.The antibody of the present application has higher binding activity with VEGF and / or ANG-2, can effectively block the binding of VEGF, ANG-2 and their respective receptors, has the effect of inhibiting angiogenesis and reducing vascular inflammation, can effectively treat or prevent the related diseases caused by angiogenesis, especially the ophthalmic related diseases.

The invention belongs to the technical field of biological medicine, and particularly relates to a traditional Chinese medicine fermentation composition for treating vascular inflammation and a preparation method thereof. The traditional Chinese medicine fermented composition for treating vascular inflammation comprises the following components in parts by mass: 1-10 parts of folium mori, 5-15 parts of bitter gourd, 5-15 parts of radix polygonati officinalis, 1-10 parts of earthworm protein, 10-20 parts of rhizoma polygonati and 5-20 parts of corn stigma. The traditional Chinese medicine fermentation composition has the effect of reducing and treating vascular inflammation, can improve the content of LDL-C and HDL-C in serum, and has good clinical guiding significance.

The present application relates to a kind of vascular inflammation prediction method based on knowledge guide and intervention-response drive, belong to artificial intelligence and medical cross technical field.It includes the following steps: acquisition multivariate physiological measurement sequence, completes missing value preprocessing using treatment-aware time series linear interpolation;Physiological and treatment sequence are explicitly decoupled into short-term acute path and long-term cumulative path, respectively through exponential decay model, low-pass filter modeling and are fused by gate mechanism, obtain treatment dynamic representation;Heterogeneous dynamic graph is constructed by fusing medical priori and data learning, executes graph convolution update node representation after treatment modulation adjacency matrix;Finally, the representation of treatment dynamics and graph enhancement is fused, and the TBR prediction value is output by attention weighting and time point specific regression.The present application can effectively separate acute and chronic treatment effects, inject clinical knowledge constraints, and is suitable for tumor survivor cardiovascular risk stratification, vascular toxicity mechanism analysis and personalized diagnosis and treatment management.

The invention discloses application of miR-29a-3p in targeting PLSCR4 and inhibiting vascular inflammation and an evaluation method of miR-29a-3p, and relates to the technical field of biomedicine.The method comprises the following steps that miR-29a-3p simulant or inhibitor is transfected to human umbilical vein endothelial cells and then stimulated with TNF-alpha, inflammatory response is evaluated through qRT-PCR, Western blot, immunofluorescence, Transwell migration, mononuclear cell chemotaxis and scanning electron microscope technologies, and therefore the inflammatory response is evaluated. According to the present invention, the PLSCR4 is identified as the miR-29a-3p direct target through the dual luciferase reporter gene experiment, the overexpression or knockout effect of the PLSCR4 is evaluated through Annexin V-PI dyeing and flow cytometry, the in vivo model of the mouse is established, the intravenous injection of the miR-29a-3p agonist is performed, and the lung tissue inflammation is analyzed by using the immunohistochemical method; the invention discloses that miR-29a-3p inhibits the activation of NLRP3 inflammasomes by down-regulating PLSCR4, so that the CASP1 mediated GSDMD cutting and subsequent cell pyroptosis pore formation are inhibited.

The present application relates to the field of biotechnology, in particular, the present application relates to single domain antibody, bispecific antibody and application thereof, more particularly, the present application relates to single domain antibody, antibody or fusion protein, bispecific antibody, nucleic acid molecule, expression vector, recombinant cell, pharmaceutical composition, pharmaceutical use, detection kit capable of specifically recognizing VEGF and / or ANG-2.The antibody of the present application has higher binding activity with VEGF and / or ANG-2, can effectively block the binding of VEGF, ANG-2 and their respective receptors, has the effect of inhibiting angiogenesis and reducing vascular inflammation, can effectively treat or prevent the related diseases caused by angiogenesis, especially the ophthalmic related diseases.

The invention provides application of a lactic dehydrogenase inhibitor in preparation of a medicine for preventing and / or treating aneurysm. The lactic dehydrogenase inhibitor is selected from a compound shown as a formula I in the specification or pharmaceutically acceptable salt thereof. Experiments show that the lactic dehydrogenase inhibitor can specifically inhibit synthesis of lactic acid in thoracic aortic aneurysm, recover expression of systolic genes, significantly inhibit vascular inflammation, maintain the systolic state of vascular smooth muscle cells and delay progress of thoracic aortic aneurysm. In addition, the lactic dehydrogenase inhibitor can also show a remarkable effect of inhibiting vasodilatation in thoracic aortic aneurysm mice, and has no remarkable influence on normal C57BL / 6J mice, so that the lactic dehydrogenase inhibitor is proved to have targeting and specific effects on thoracic aortic aneurysm. The lactic dehydrogenase inhibitor can also significantly inhibit vascular wall inflammatory response and elastic fiber destruction and delay the progress of thoracic aortic aneurysm by recovering the steady state function of vascular smooth muscle cells.

The present application relates to the field of medicine, in particular to the use of POU2F2 gene or protein in screening products for preventing or treating atherosclerosis. The present application first discloses that POU2F2 can be used as a key pathogenic target of atherosclerosis, and on this basis, a candidate drug linagliptin is screened. The experimental results show that in the in vitro atherosclerosis model, linagliptin can significantly inhibit the expression of POU2F2 and down-regulate the levels of inflammatory factors and adhesion molecules. The findings clarify the mechanism of linagliptin in regulating POU2F2 related signal pathways, inhibiting vascular inflammatory response and reducing vascular endothelial damage, and fully show that it has a good clinical application prospect in preparing drugs for preventing or treating atherosclerosis and its related cardiovascular and cerebrovascular diseases.

The present invention describes a new functional biomarker of vascular inflammation and its use in predicting all-cause or cardiac mortality. The invention also provides a method for stratifying patients according to their risk of all-cause or cardiac mortality using data gathered from a computer tomography scans of a blood vessel to determine a specific combination of structural and functional biomarkers of vascular inflammation and disease.

The present invention relates to the field of nanoparticles, conjugates thereof, and their use in methods of treating or preventing vascular inflammation. The present invention also relates to methods of delivering an agent to a region of a patient's blood vessel, comprising: a) conjugating an agent to a nanoparticle to produce a conjugate; and b) delivering the conjugate to a region of a blood vessel.

The invention discloses a traditional Chinese medicine composition and application thereof in preparation of a medicine for treating vascular inflammation and endothelial injury, and relates to the technical field of traditional Chinese medicines. The traditional Chinese medicine composition is prepared from the following medicinal raw materials in parts by weight: 40-60 parts of artemisia vestita, 40-55 parts of semen lepidii, 30-40 parts of shellac, 20-25 parts of phyllanthus emblica, 15-30 parts of astragalus membranaceus, 10-20 parts of salvia miltiorrhiza, 8-15 parts of radix paeoniae rubra, 3-9 parts of coptis chinensis and 1-5 parts of leech. The traditional Chinese medicine composition is good in safety and good in effect, and animal experiments prove that the traditional Chinese medicine composition has a good effect on treating vascular inflammation and endothelial injury.

The present invention relates to a pharmaceutical composition comprising an autotaxin inhibitor as an active ingredient for preventing or treating calcification-related diseases. Specifically, the autotaxin inhibitor is useful for the prevention or treatment of calcification-related diseases such as vascular calcification, vascular stiffening, vascular inflammation, vascular fibrosis, vascular stenosis, valvular calcification, valvular inflammation, valvular fibrosis, aortic valve stenosis, and calcinosis cutis.

The present disclosure generally relates to methods for the treatment, amelioration, and / or prevention of vascular inflammatory disorders. In some aspects, the methods of the present disclosure comprise administration of an EZH2 inhibitor in a therapeutically effective amount to a subject in need thereof in order to treat, ameliorate, and / or prevent a vascular inflammatory disorder. In some aspects, the methods of the present disclosure comprise administration of an EZH2 inhibitor in a therapeutically effective amount to a subject in need thereof in order to treat, ameliorate, and / or prevent a cardiovascular disease.

The invention belongs to the technical field of biological medicines, and particularly relates to application of deaminotyrosine in preparation of medicines for preventing and treating atherosclerosis. In-vivo and in-vitro experiments show that the deaminated tyrosine can effectively inhibit foaming of macrophages, relieve vascular inflammation, remarkably reduce the atherosclerotic plaque area of ApoE- / -mice, reduce the atherosclerotic plaque area of ApoE- / -mice, and improve the Therefore, the invention provides a new application of the deaminated tyrosine or pharmaceutically acceptable salts, esters, solvates or prodrugs thereof in preparation of drugs for treating or preventing atherosclerosis, and provides a scientific basis and a core technology for development of the deaminated tyrosine as a brand-new, multi-target and high-safety anti-atherosclerosis drug.

The invention provides a multi-microsphere flow type fluorescence detection method for vascular inflammation markers, and belongs to the technical field of multi-microsphere flow type fluorescence detection.The multi-microsphere flow type fluorescence detection method comprises the steps that capture antibody coupling microsphere mixed liquor with different fluorescence coding characteristics is prepared; the method comprises the following steps: sequentially reacting with a to-be-detected sample, a biotin labeled detection antibody and phycoerythrin labeled streptavidin to form a sandwich immune complex, collecting a fluorescence signal by using a flow cytometry, and then carrying out self-adaptive optimization treatment on the original fluorescence signal by using a liquid dynamic correction model, according to the dynamic response characteristics of liquid neurons in the liquid reservoir layer, accurate concentration results of the five vascular inflammation markers are calculated by fitting a standard curve through a logistic regression model, and the technical problem that the multiple detection precision of the vascular inflammation markers is insufficient due to limited dynamic range of fluorescence signals and serious background noise interference is solved.

To provide an active ingredient delivery tool that provides a complex formulation capable of improving vascular endothelial function, vascular inflammation, arteriosclerosis, and vascular calcification. [Solution] The active ingredient delivery tool (100) includes a rectangular box-shaped adsorption structure (110), an oval or circular Bacillus subtilis structure (120), an oval or circular active ingredient structure (130), and an oval or circular edible gel structure (140). The material of the adsorption structure is non-nanoscale montmorillonite. The Bacillus subtilis structure covers the outside of the adsorption structure. The active ingredient structure covers the outside of the Bacillus subtilis structure. The edible gel structure covers the outside of the active ingredient structure. The edible gel structure provides stability, viscosity, and encapsulation functions to the active ingredient delivery tool, and is a complex formulation that can improve vascular endothelial function, vascular inflammation, arteriosclerosis, and vascular calcification.

The invention discloses a nutritional supplement rich in omega 3 and antioxidant and anti-aging factors, and belongs to the technical field of nutritional supplements. The supplement is prepared by taking purple perilla seeds as a core raw material, matching with turmeric, allicin and shaddock peel components and compounding according to a scientific ratio. Wherein the fructus perillae is rich in omega 3 (mainly alpha-linolenic acid with the content of 50%-70%), and can be converted into DHA and EPA in a human body, so that the health of heart and cerebral vessels can be maintained, and the eyesight and memory can be improved; flavonoid substances such as curcumin and allicin in the rhizoma curcumae longae and naringin and the like in the shaddock peel have remarkable anti-oxidation, anti-inflammatory and anti-aging capacities, and can scavenge free radicals, slow down cell aging and inhibit vascular inflammation. All the components have a synergistic effect, the problem of function limitation of a single nutritional supplement is solved, omega 3 nutritional support and anti-oxidation and anti-aging protection can be comprehensively provided for human bodies, and the nutritional supplement is suitable for people who need daily nutritional supplement and pay attention to oxidation and aging resistance and has a wide application prospect.